Skip to main content Skip to section navigation Skip to footer
Capricor Therapeutics, Inc.
  • Home
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisors (DMD)
  • Our Science
    • Deramiocel (Biologic Medicine)
    • Exosomes Technology
    • Publications
    • Strategic Partnerships
  • Pipeline
    • Pipeline
    • Duchenne Muscular Dystrophy Overview
    • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • In the News
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Leadership
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Latest Proxy Statement and Annual Report
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity
  • News & Events

  • Overview
  • Press Releases
  • In the News
  • IR Calendar
  • Presentations
  • Email Alerts
Feb 23, 2017 8:00 am EST

Capricor Therapeutics to Present at Two Investor Conferences in March

Feb 16, 2017 5:01 pm EST

Capricor Therapeutics Provides Update on Natriuretic Peptide Program

Feb 07, 2017 7:00 am EST

Capricor Therapeutics to Present at the 2017 BIO CEO and Investor Conference

Nov 21, 2016 7:00 am EST

Capricor Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference

Nov 10, 2016 4:07 pm EST

Capricor Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update

Nov 10, 2016 4:05 pm EST

Capricor Therapeutics Announces Plans to Expand Clinical Development Program in Duchenne Muscular Dystrophy to Evaluate Peripheral and Respiratory Muscle Function

Nov 03, 2016 7:00 am EDT

Capricor Therapeutics to Hold Third Quarter 2016 Business Update and Financial Results Conference Call and Webcast on Thursday, November 10 at 5:00 p.m. ET

Oct 31, 2016 9:00 am EDT

Capricor Therapeutics Presents Positive 12-Month Results from DYNAMIC at TCT 2016

Oct 20, 2016 7:00 am EDT

Capricor Therapeutics Awarded Up to $4.2 Million from National Institutes of Health to Evaluate Exosomes for Hypoplastic Left Heart Syndrome

Oct 05, 2016 7:00 am EDT

Capricor Therapeutics Completes Enrollment in Phase II ALLSTAR Clinical Trial

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • Page 24
  • Page 25
  • Page 26
  • Page 27
  • …
  • Page 31
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed
  • Visit us on Linkedin
  • Visit us on Facebook
  • Visit us on Instagram
  • Visit us on Twitter
©2025 Capricor Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap Manage Cookie Preferences